BACKGROUND: Multiple studies have suggested that resection of the primary tumor improves survival in patients with stage IV breast cancer, yet in the era of targeted therapy, the relation between surgery and tumor molecular subtype is unknown. The objective of the current study was to identify subsets of patients who may benefit from primary tumor treatment and assess the frequency of local disease progression. METHODS: Patients presenting with stage IV breast cancer and intact primary tumors (n = 186) were identified from a prospectively maintained clinical database (2000-2004) and clinical data were abstracted (grading determined according to the American Joint Committee on Cancer staging system). RESULTS: Surgery was performed in 69 (37%) patients: 34 (49%) patients with unknown metastatic disease at the time of surgery, 15 (22%) patients for local control, 14 (20%) patients for palliation, and in 6 (9%) patients to obtain tissue. Surgical patients were more likely to be HER-2/neu negative (P = .001), and to have smaller tumors (P = .05) and solitary metastasis (P <.001). Local therapy included axillary lymph node clearance in 33 (48%) patients and postoperative radiotherapy in 9 (13%) patients. The median survival was 35 months. Cox regression analysis identified estrogen receptor (ER) positivity (hazard ratio [HR], 0.47; 95% confidence interval [95% CI], 0.29-0.76), progesterone receptor (PR) positivity (HR, 0.57; 95% CI, 0.36-0.90), and HER-2/neu amplification (HR, 0.51; 95% CI, 0.34-0.77) as being predictive of improved survival. There was a trend toward improved survival with surgery (HR, 0.71; 95% CI, 0.47-1.06). On exploratory analyses, surgery was found to be associated with improved survival in patients with ER/PR positive or HER-2/neu-amplified disease (P = .004). No survival benefit was observed in patients with triple-negative disease. CONCLUSIONS: Although a trend toward improved survival with surgery was observed, it was noted most strongly in patients with ER/PR positive and/or HER-2/neu-amplified disease. This suggests that the impact of local control is greatest in the presence of effective targeted therapy, and supports the need for further study to define patient subsets that will benefit most.
BACKGROUND: Multiple studies have suggested that resection of the primary tumor improves survival in patients with stage IV breast cancer, yet in the era of targeted therapy, the relation between surgery and tumor molecular subtype is unknown. The objective of the current study was to identify subsets of patients who may benefit from primary tumor treatment and assess the frequency of local disease progression. METHODS:Patients presenting with stage IV breast cancer and intact primary tumors (n = 186) were identified from a prospectively maintained clinical database (2000-2004) and clinical data were abstracted (grading determined according to the American Joint Committee on Cancer staging system). RESULTS: Surgery was performed in 69 (37%) patients: 34 (49%) patients with unknown metastatic disease at the time of surgery, 15 (22%) patients for local control, 14 (20%) patients for palliation, and in 6 (9%) patients to obtain tissue. Surgical patients were more likely to be HER-2/neu negative (P = .001), and to have smaller tumors (P = .05) and solitary metastasis (P <.001). Local therapy included axillary lymph node clearance in 33 (48%) patients and postoperative radiotherapy in 9 (13%) patients. The median survival was 35 months. Cox regression analysis identified estrogen receptor (ER) positivity (hazard ratio [HR], 0.47; 95% confidence interval [95% CI], 0.29-0.76), progesterone receptor (PR) positivity (HR, 0.57; 95% CI, 0.36-0.90), and HER-2/neu amplification (HR, 0.51; 95% CI, 0.34-0.77) as being predictive of improved survival. There was a trend toward improved survival with surgery (HR, 0.71; 95% CI, 0.47-1.06). On exploratory analyses, surgery was found to be associated with improved survival in patients with ER/PR positive or HER-2/neu-amplified disease (P = .004). No survival benefit was observed in patients with triple-negative disease. CONCLUSIONS: Although a trend toward improved survival with surgery was observed, it was noted most strongly in patients with ER/PR positive and/or HER-2/neu-amplified disease. This suggests that the impact of local control is greatest in the presence of effective targeted therapy, and supports the need for further study to define patient subsets that will benefit most.
Authors: Gildy V Babiera; Roshni Rao; Lei Feng; Funda Meric-Bernstam; Henry M Kuerer; S Eva Singletary; Kelly K Hunt; Merrick I Ross; Karin M Gwyn; Barry W Feig; Frederick C Ames; Gabriel N Hortobagyi Journal: Ann Surg Oncol Date: 2006-04-17 Impact factor: 5.344
Authors: Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou Journal: Clin Cancer Res Date: 2007-04-15 Impact factor: 12.531
Authors: Elisabetta Rapiti; Helena M Verkooijen; Georges Vlastos; Gerald Fioretta; Isabelle Neyroud-Caspar; André Pascal Sappino; Pierre O Chappuis; Christine Bouchardy Journal: J Clin Oncol Date: 2006-05-15 Impact factor: 44.544
Authors: Roshni Rao; Lei Feng; Henry M Kuerer; S Eva Singletary; Isabelle Bedrosian; Kelly K Hunt; Merrick I Ross; Gabriel N Hortobagyi; Barry W Feig; Frederick C Ames; Gildy V Babiera Journal: Ann Surg Oncol Date: 2008-03-21 Impact factor: 5.344
Authors: Andrea C Bafford; Harold J Burstein; Christina R Barkley; Barbara L Smith; Stuart Lipsitz; James D Iglehart; Eric P Winer; Mehra Golshan Journal: Breast Cancer Res Treat Date: 2008-06-26 Impact factor: 4.872
Authors: Ana C Gregório; Manuela Lacerda; Paulo Figueiredo; Sérgio Simões; Sérgio Dias; João Nuno Moreira Journal: Pathol Oncol Res Date: 2017-09-14 Impact factor: 3.201
Authors: Laura Dominici; Julie Najita; Melissa Hughes; Joyce Niland; Paul Marcom; Yu-Ning Wong; Bradford Carter; Sara Javid; Stephen Edge; Harold Burstein; Mehra Golshan Journal: Breast Cancer Res Treat Date: 2011-06-29 Impact factor: 4.872
Authors: S Samiee; P Berardi; N Bouganim; L Vandermeer; A Arnaout; S Dent; D Mirsky; M Chasen; J M Caudrelier; M Clemons Journal: Curr Oncol Date: 2012-08 Impact factor: 3.677
Authors: Ross Mudgway; Carlos Chavez de Paz Villanueva; Ann C Lin; Maheswari Senthil; Carlos A Garberoglio; Sharon S Lum Journal: Ann Surg Oncol Date: 2020-03-10 Impact factor: 5.344